The benefits and challenges associated with the use of drug delivery systems in cancer therapy
about
The Research and Applications of Quantum Dots as Nano-Carriers for Targeted Drug Delivery and Cancer TherapyUse of Targeted Liposome-based Chemotherapeutics to Treat Breast CancerDelivery of host cell-directed therapeutics for intracellular pathogen clearanceThe wound healing, chronic fibrosis, and cancer progression triadA novel PEGylated liposome-encapsulated SANT75 suppresses tumor growth through inhibiting hedgehog signaling pathwayAbraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gpCharacterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo.Bromelain surface modification increases the diffusion of silica nanoparticles in the tumor extracellular matrixMiniaturized pre-clinical cancer models as research and diagnostic tools.Block copolymer micelles for controlled delivery of glycolytic enzyme inhibitors.Development, characterization, and in vitro evaluation of tamoxifen microemulsions.Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo.The mesenchymal tumor microenvironment: a drug-resistant niche.Nanotechnology and drug delivery: an update in oncology.The treatment of breast cancer using liposome technology.Analysis on the current status of targeted drug delivery to tumorsExploitation of viral properties for intracellular delivery.The bioactivity and toxicological actions of carvacrol.Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.Fusogenic pH sensitive liposomal formulation for rapamycin: improvement of antiproliferative effect.Polymersomes from polypeptide containing triblock Co- and terpolymers for drug delivery against pancreatic cancer: asymmetry of the external hydrophilic blocks.Tumor-preferential sustained drug release enhances antitumor activity of block copolymer micelles.Plasma stable, pH-sensitive fusogenic polymer-modified liposomes: A promising carrier for mitoxantrone.Drug release patterns and cytotoxicity of PEG-poly(aspartate) block copolymer micelles in cancer cells.Chronic exposure to agmatine results in the selection of agmatine-resistant hepatoma cells.Clickable functionalization of liposomes with the gH625 peptide from Herpes simplex virus type I for intracellular drug delivery.Designing colon-specific delivery systems for anticancer drug-loaded nanoparticles: an evaluation of alginate carriers.Pharmaceutical potential of quantum dots.Disulfide bond based polymeric drug carriers for cancer chemotherapy and relevant redox environments in mammals.Liposome encapsulated luteolin showed enhanced antitumor efficacy to colorectal carcinoma.Use of mathematical models to understand anticancer drug delivery and its effect on solid tumors.PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems.Cascaded Photoinduced Drug Delivery to Cells from Multifunctional Core-Shell Mesoporous SilicaSynthesis, Characterization, andIn VitroDrug Delivery Capabilities of (Zn, Al)-Based Layered Double Hydroxide Nanoparticles
P2860
Q26752676-6F8F4DAC-1AC6-4BA6-B256-27AC7D232D36Q26797230-0D93FB77-BCCF-4478-AB2A-9618D2683283Q27006858-14BEB26B-DE58-4125-A3BF-8F3426A1B88DQ27014616-A851FE6B-771D-4DC7-B297-B058B98B0E86Q28485870-E73B8E5C-F4DD-489A-886A-38F1AF65226DQ28546603-66100697-63CB-41E1-87DB-22AF4EFBB2BAQ30475089-2AA72558-1C7D-4D7F-9BE3-2BC7217B67F5Q30596466-87CE7528-BDDE-43A1-A7EF-9C9F5F0CA770Q33605145-EF9CDEE5-75C9-4E49-B029-BB3E34D594EEQ34060289-4B3ED132-9122-4183-8F27-B25469C30874Q35681427-B764E5FE-0D9F-487F-8919-8EEEE8421DF5Q36158947-532D3DCF-4208-41C1-BD79-B3D005352759Q36187755-12DD047B-E0C5-4BE9-BEF1-D4C56BFA49E0Q37394893-70339E0B-481E-49B6-882F-D22E42C18E6AQ38002854-61B884EB-8D0A-4F51-991B-169D39ED3A3CQ38026625-1DF4DC2B-148C-4609-8436-788E1912BF6CQ38216947-B9B4935F-6AC1-4AC2-BDC0-1FC0DBAE78C5Q38219186-3AD4C6DF-4BAA-46A2-8E2F-85D8115242BAQ38856533-1E89965D-D539-4779-A805-A784F4A7BBFBQ38985738-50DF0ADE-4BD6-4F9D-B111-5E912B1A3924Q38994012-514CEEF3-EBDB-444F-83DF-1DFF7F9291CFQ39001276-1B321D8D-3304-4C0B-94DC-E8D2EB7A5995Q39043619-5BF0D0F0-FEB3-444B-862A-ACBAB1D6134BQ39398627-DDB4E530-D3D6-49DF-8FDE-9A71E8C5F71EQ39477464-CD6DA1F9-B706-4C46-A18F-2ADE9702B99DQ45362938-8192A7AA-96FD-47B9-B177-3AB4DDAF58E7Q45893381-12FAD8AA-782B-48A7-A492-032DD5E90AB6Q47272061-5411E60A-35E8-4E1D-B3A2-D65EFB4117F7Q48228957-F1730E2B-AFCA-4C1F-AAA2-710B45C7CFECQ49187796-2B5E2A1E-0036-4FD6-81A1-69986B8F2BD7Q51532050-DFA29D52-3538-4548-BCD7-18946FA3EA3EQ52688323-5FCE6E62-D412-4F4F-9ABF-F89DEA722F8AQ57447918-3480667D-3727-4083-BC0A-36249402B3E8Q59114146-5D998087-65B3-4380-80F6-E43B7121F8EF
P2860
The benefits and challenges associated with the use of drug delivery systems in cancer therapy
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The benefits and challenges as ...... very systems in cancer therapy
@ast
The benefits and challenges as ...... very systems in cancer therapy
@en
type
label
The benefits and challenges as ...... very systems in cancer therapy
@ast
The benefits and challenges as ...... very systems in cancer therapy
@en
prefLabel
The benefits and challenges as ...... very systems in cancer therapy
@ast
The benefits and challenges as ...... very systems in cancer therapy
@en
P2860
P1476
The benefits and challenges as ...... very systems in cancer therapy
@en
P2093
David R Khan
Edna Cukierman
P2860
P304
P356
10.1016/J.BCP.2010.04.020
P407
P577
2010-04-22T00:00:00Z